These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29453908)

  • 1. Effective anti-adhesives of uropathogenic Escherichia coli.
    Ribić R; Meštrović T; Neuberg M; Kozina G
    Acta Pharm; 2018 Mar; 68(1):1-18. PubMed ID: 29453908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposed dual antagonist approach for the prevention and treatment of urinary tract infections caused by uropathogenic Escherichia coli.
    Ribić R; Meštrović T; Neuberg M; Kozina G
    Med Hypotheses; 2019 Mar; 124():17-20. PubMed ID: 30798908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
    Spaulding CN; Klein RD; Ruer S; Kau AL; Schreiber HL; Cusumano ZT; Dodson KW; Pinkner JS; Fremont DH; Janetka JW; Remaut H; Gordon JI; Hultgren SJ
    Nature; 2017 Jun; 546(7659):528-532. PubMed ID: 28614296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classical chaperone-usher (CU) adhesive fimbriome: uropathogenic Escherichia coli (UPEC) and urinary tract infections (UTIs).
    Behzadi P
    Folia Microbiol (Praha); 2020 Feb; 65(1):45-65. PubMed ID: 31165977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.
    Greene SE; Hibbing ME; Janetka J; Chen SL; Hultgren SJ
    mBio; 2015 Jun; 6(4):e00820. PubMed ID: 26126855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of acute urinary tract infections caused by uropathogenic
    Pullanhi U; Khan S; Vinod V; Mohan K; Kumar A
    Ann Afr Med; 2019; 18(3):138-142. PubMed ID: 31417014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteolin decreases the attachment, invasion and cytotoxicity of UPEC in bladder epithelial cells and inhibits UPEC biofilm formation.
    Shen XF; Ren LB; Teng Y; Zheng S; Yang XL; Guo XJ; Wang XY; Sha KH; Li N; Xu GY; Tian HW; Wang XY; Liu XK; Li J; Huang N
    Food Chem Toxicol; 2014 Oct; 72():204-11. PubMed ID: 25051393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Consumption of Cranberry Exerts ex Vivo Antiadhesive Activity against FimH-Dominated Uropathogenic Escherichia coli: A Combined in Vivo, ex Vivo, and in Vitro Study of an Extract from Vaccinium macrocarpon.
    Rafsanjany N; Senker J; Brandt S; Dobrindt U; Hensel A
    J Agric Food Chem; 2015 Oct; 63(40):8804-18. PubMed ID: 26330108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.
    Guiton PS; Cusumano CK; Kline KA; Dodson KW; Han Z; Janetka JW; Henderson JP; Caparon MG; Hultgren SJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4738-45. PubMed ID: 22733070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile.
    Kleeb S; Pang L; Mayer K; Eris D; Sigl A; Preston RC; Zihlmann P; Sharpe T; Jakob RP; Abgottspon D; Hutter AS; Scharenberg M; Jiang X; Navarra G; Rabbani S; Smiesko M; Lüdin N; Bezençon J; Schwardt O; Maier T; Ernst B
    J Med Chem; 2015 Mar; 58(5):2221-39. PubMed ID: 25666045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virulence factors of uropathogenic E. coli and their interaction with the host.
    Lüthje P; Brauner A
    Adv Microb Physiol; 2014; 65():337-72. PubMed ID: 25476769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative proteomics of uropathogenic Escherichia coli during growth in human urine identify UCA-like (UCL) fimbriae as an adherence factor involved in biofilm formation and binding to uroepithelial cells.
    Wurpel DJ; Totsika M; Allsopp LP; Webb RI; Moriel DG; Schembri MA
    J Proteomics; 2016 Jan; 131():177-189. PubMed ID: 26546558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.
    Klein T; Abgottspon D; Wittwer M; Rabbani S; Herold J; Jiang X; Kleeb S; Lüthi C; Scharenberg M; Bezençon J; Gubler E; Pang L; Smiesko M; Cutting B; Schwardt O; Ernst B
    J Med Chem; 2010 Dec; 53(24):8627-41. PubMed ID: 21105658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.
    Asadi Karam MR; Habibi M; Bouzari S
    Mol Immunol; 2019 Apr; 108():56-67. PubMed ID: 30784763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Regulation of the Diguanylate Cyclase YaiC Reduces Production of Type 1 Fimbriae in a Pst Mutant of Uropathogenic Escherichia coli CFT073.
    Crépin S; Porcheron G; Houle S; Harel J; Dozois CM
    J Bacteriol; 2017 Dec; 199(24):. PubMed ID: 28924030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A flow cytometry-based assay for screening FimH antagonists.
    Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B
    Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of virulence determinants among antimicrobial-resistant and antimicrobial-susceptible
    Stephenson S; Brown PD
    Indian J Med Microbiol; 2016; 34(4):448-456. PubMed ID: 27934822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial Agents and Urinary Tract Infections.
    Issakhanian L; Behzadi P
    Curr Pharm Des; 2019; 25(12):1409-1423. PubMed ID: 31218955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.